Citing RBC Capital Markets analyst, Reuters noted that an approval is expected in the second half of 2024, versus Eisai's expectation of a decision in the quarter ending June 30. Read Next: Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision. Price Action: BIIB shares are down 1.10% at $218.32 on the last check Friday. Photo via Shutterstock